FIELD: pharmacology.
SUBSTANCE: invention concerns novel compounds of formula (1a) or (1b) or their pharmaceutically acceptable salts with inhibition effect on matrix metalloproteinases (MMP). In formula
or T is absent; G1 and G2 is independently CH or N; A is C1-6alkyl; B is a link; D is a link; E is phenyl substituted by condensed heterocyclic ring in the form of nitrogen-containing ring which can be substituted by carbonyl groups; or substituted 6-membered heteroaryl or bicyclic heteroaryl where second ring in bicyclic system is benzene ring, and heteroaryl is 5-6-membered ring containing 1, 2 or 3 nitrogen heteroatoms, and heteroaryl is substituted by 1, 2 and 3 groups selected out of oxo and C1-6alkyl-; R16 is C1-6alkyl; R18 is halogeno, cyano, nitro, OR16 , OCF3, SR16 or COR16; m is 0 or integer 1 or 2; n is 0.
EFFECT: obtaining compounds and pharmaceutical composition based on them.
13 cl, 18 ex
Title | Year | Author | Number |
---|---|---|---|
CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM | 2018 |
|
RU2795146C2 |
2,5-DISUBSTITUTED 3-MERCAPTOPENTANIC ACIDS AND METHOD OF OBTAINING THEM | 2003 |
|
RU2365583C2 |
7-SUBSTITUTED SULFONIMIDOYLPURINONES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION | 2017 |
|
RU2751349C2 |
HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | 2018 |
|
RU2764243C2 |
CONDENSED HETEROCYCLIC SUCCINAMIDE COMPOUNDS | 2001 |
|
RU2298554C2 |
PROPOSED 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | 2022 |
|
RU2826000C1 |
QUINOLINE DERIVATIVES AS SMO INHIBITORS | 2015 |
|
RU2695815C2 |
GUANIDIN DERIVATIVES AND THEIR APPLICATION AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | 2004 |
|
RU2337911C2 |
PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
ISOINDOLINONE INHIBITORS OF MDM2-P53 INTERACTION WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2794333C1 |
Authors
Dates
2009-10-20—Published
2004-09-10—Filed